Windward Bio Group AG is a clinical-stage biopharmaceutical company focused on the discovery, licensing, and clinical development of differentiated, ultra-long-acting biologic therapeutics targeting clinically validated immunological pathways. The company operates primarily from Basel, Switzerland, with corporate operations also established in the United States, and holds commercialization rights to its clinical-stage assets outside Greater China. Windward Bio operates in a single operating segment focused on research and drug development and is pre-revenue, having generated no commercial product sales since inception. Its pipeline is anchored by two primary clinical assets: WIN378, an ultra-long-acting fully human monoclonal antibody designed to inhibit TSLP, currently being evaluated in a Phase 2/3 study (POLARIS-1) for severe uncontrolled asthma and a Phase 2 study (SIRIUS) for COPD with a target twice-yearly subcutaneous dosing regimen; and WIN027, an investigational long-acting bispecific antibody designed to neutralize both TSLP and IL-13 simultaneously, undergoing Phase 1 evaluation with planned Phase 2 studies in COPD and atopic dermatitis. The company also maintains internal discovery research to feed its pipeline of bispecific antibodies. Windward Bio targets substantial therapeutic markets including severe asthma, COPD, and atopic dermatitis, competing against approved biologic standards of care such as tezepelumab (Tezspire) and dupilumab (Dupixent). Its competitive positioning centers on optimized molecular design aimed at substantially longer dosing intervals (e.g., semi-annual subcutaneous injections) and dual-pathway cytokine inhibition, designed to improve real-world treatment adherence and disease control.
The sum of declared dividends issued by a company for every ordinary share outstanding.
Dividend Yield is a financial ratio that shows how much a company pays out in dividends each year relative to its share price in the last twelve months. In the absence of any capital gains, the dividend yield is the return on investment for a stock.
It is another way that companies have to remunerate their shareholders, being an alternative to dividends. Shows the % of repurchases per share made in the last 12 months in relation to the share price.
Sum of Dividend Yield and BuyBack Yield to show the total return that the shareholder received in the last 12 months in relation to the share price.
The dividend payout ratio is the ratio of the total amount of dividends paid out to shareholders relative to the net income of the company. It is the percentage of earnings paid to shareholders via dividends.
Retained earnings (RE) are the amount of net income left over for the business after it has paid out dividends to its shareholders and are an important variable for assessing a company's financial health because it shows the net income that a company has saved over time, and therefore has the ability to reinvest in the business or distribute to shareholders.
...and much more!